Table 1_Case Report: Upadacitinib treatment for Behçet’s syndrome with intestinal damage.docx

We report the case of a 17-year-old male presenting with recurrent, debilitating oral and genital ulcerations. Diagnostic evaluation confirmed multisystemic Behçet’s syndrome with multifocal intestinal involvement. Following the exclusion of infectious contraindications, the patient was initiated on upadacitinib (15 mg daily) as a primary systemic intervention. Remarkable clinical remission of mucocutaneous and gastrointestinal ulcerations was achieved within 1 month. Sustained improvement was observed during subsequent follow-up, suggesting that upadacitinib may serve as an effective therapy for multisystemic Behçet’s syndrome in adolescent patients.